CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07216703 · Merck & Co., Inc · Phase 3 · live · background · “Carboplatin” · registered Oct 2025
- NCT07168200 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Carboplatin Injection” · registered Sep 2025
- NCT06859775 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Carboplatin injection” · registered Feb 2025
- NCT06535607 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Jul 2024
- NCT06241235 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2 · live · background · “Carboplatin” · registered Jan 2024
| Eli Lilly and Company16% of its industry studies | 911 studies | 1114 studies | background 21 · comparator 1 |
PaclitaxelRecent, repeatedEvidence- NCT07418749 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel for Injection (Albumin bound)” · registered Feb 2026
- NCT07216703 · Merck & Co., Inc · Phase 3 · live · background · “Paclitaxel” · registered Oct 2025
- NCT07168200 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Paclitaxel Injection” · registered Sep 2025
- NCT06535607 · AstraZeneca · Phase 2 · live · background · “Paclitaxel” · registered Jul 2024
- NCT06241235 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2 · live · background · “Paclitaxel” · registered Jan 2024
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 810 studies | 1013 studies | background 19 · comparator 2 |
BevacizumabRecent, repeatedEvidence- NCT07497074 · Alphamab Oncology · Phase 2 · live · background · “Bevacizumab” · registered Mar 2026
- NCT07216703 · Merck & Co., Inc · Phase 3 · live · background · “Bevacizumab” · registered Oct 2025
- NCT07080216 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2 · live · background · “Bevacizumab” · registered Jul 2025
- NCT07054567 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Bevacizumab” · registered Jun 2025
- NCT06859775 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Bevacizumab injection” · registered Feb 2025
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 89 studies | 89 studies | background 16 |
CisplatinRecent, repeatedEvidence- NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Cisplatin” · registered Aug 2026
- NCT07216703 · Merck & Co., Inc · Phase 3 · live · background · “Cisplatin” · registered Oct 2025
- NCT07168200 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Cisplatin Injection” · registered Sep 2025
- NCT06859775 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Cisplatin injection” · registered Feb 2025
- NCT06535607 · AstraZeneca · Phase 2 · live · background · “Cisplatin” · registered Jul 2024
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 710 studies | 710 studies | background 21 · comparator 1 |
pembrolizumabRecent, repeatedEvidence- NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT07054567 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Jun 2025
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2023
- NCT05579366 · Genmab · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2022
- NCT05081609 · Ascendis Pharma Oncology Division A/S · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2021
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 44 studies | 66 studies | background 7 |
GemcitabineRecent, repeatedEvidence- NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Gemcitabine” · registered Aug 2026
- NCT07797153 · Alphamab Oncology · Phase 3 · live · comparator · “Gemcitabine (GEM)” · registered Aug 2026
- NCT07418749 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine Hydrochloride for Injection” · registered Feb 2026
- NCT06459180 · Merck & Co., Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Jun 2024
- NCT06241781 · Grit Biotechnology · Phase 2 · live · comparator · “Gemcitabine injection” · registered Jan 2024
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 45 studies | 45 studies | comparator 6 · background 2 |
DocetaxelRecent, repeatedEvidence- NCT07797153 · Alphamab Oncology · Phase 3 · live · comparator · “Docetaxel” · registered Aug 2026
- NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
- NCT05383482 · Laekna Limited · Phase 2 · background · “Docetaxel” · registered Apr 2022
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Docetaxel” · registered Aug 2021
- NCT04895709 · Bristol-Myers Squibb · Phase 2 · live · background · “Docetaxel” · registered May 2021
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 33 studies | 55 studies | background 6 · comparator 1 |
FulvestrantRecent, repeatedEvidence- NCT07109726 · Terremoto Biosciences Inc. · Phase 2 · live · background · “Fulvestrant injection” · registered Jul 2025
- NCT06993844 · Ensem Therapeutics · Phase 2 · live · background · “ETX-636 dose escalation in combination with fulvestrant” · registered May 2025
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Fulvestrant” · registered Mar 2023
- NCT04579380 · Pfizer · Phase 2 · live · background · “fulvestrant” · registered Oct 2020
| AstraZeneca70% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 1 generic authorized | 33 studies | 44 studies | background 4 |
TopotecanRecent, repeatedEvidence- NCT07797153 · Alphamab Oncology · Phase 3 · live · comparator · “Topotecan” · registered Aug 2026
- NCT07418749 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Topotecan Hydrochloride for Injection” · registered Feb 2026
- NCT06459180 · Merck & Co., Inc · Phase 3 · live · comparator · “Topotecan” · registered Jun 2024
- NCT04943627 · Agenus Inc. · Phase 3 · comparator · “Topotecan” · registered Jun 2021
- NCT04697628 · Pfizer · Phase 3 · comparator · “topotecan” · registered Jan 2021
| GlaxoSmithKline55% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 1 generic authorized | 33 studies | 33 studies | comparator 5 · background 2 |
PemetrexedRecent, repeatedEvidence- NCT07797153 · Alphamab Oncology · Phase 3 · live · comparator · “Pemetrexed” · registered Aug 2026
- NCT07418749 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Pemetrexed Disodium for Injection” · registered Feb 2026
- NCT06459180 · Merck & Co., Inc · Phase 3 · live · comparator · “Pemetrexed” · registered Jun 2024
- NCT04943627 · Agenus Inc. · Phase 3 · comparator · “Pemetrexed” · registered Jun 2021
- NCT04697628 · Pfizer · Phase 3 · comparator · “pemetrexed” · registered Jan 2021
| Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized | 33 studies | 33 studies | comparator 5 |
IrinotecanRecent, repeatedEvidence- NCT06459180 · Merck & Co., Inc · Phase 3 · live · comparator · “Irinotecan” · registered Jun 2024
- NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Irinotecan (Camptosar)” · registered Oct 2022
- NCT04943627 · Agenus Inc. · Phase 3 · comparator · “Irinotecan” · registered Jun 2021
- NCT04697628 · Pfizer · Phase 3 · comparator · “irinotecan” · registered Jan 2021
| Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016) | 22 studies | 22 studies | comparator 3 · background 1 |
FluorouracilRecent, repeatedEvidence- NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “5-Fluorouracil” · registered Aug 2026
- NCT06535607 · AstraZeneca · Phase 2 · live · background · “5-FU” · registered Jul 2024
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “5-Fluorouracil” · registered Aug 2021
| Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed | 22 studies | 22 studies | background 3 |
Human Papillomavirus Recombinant Vaccine nonavalentRecent, repeatedPhase 4 trial recordedEvidence- NCT05662020 · Beijing Health Guard Biotechnology, Inc · Phase 3 · live · comparator · “GARDASIL® 9” · registered Dec 2022
- NCT05580341 · Shanghai Zerun Biotechnology Co.,Ltd · Phase 3 · comparator · “GARDASIL ®9” · registered Oct 2022
- NCT05372016 · Shanghai Bovax Biotechnology Co., Ltd. · Phase 3 · comparator · “Active Comparator: GARDASIL ®9” · registered Dec 2020
| Merck & Co., Inc80% of its industry studies | 22 studies | 11 study | comparator 3 |
Interleukin-2Recent, repeatedPhase 4 trial recordedEvidence- NCT06241781 · Grit Biotechnology · Phase 2 · live · background · “IL-2” · registered Jan 2024
- NCT05357027 · TCRCure Biopharma Ltd. · Phase 2 · background · “IL-2” · registered Jan 2022
| Chiron Corporation27% of its industry studies | 22 studies | 11 study | background 2 |
fludarabineRecent, repeatedPhase 4 trial recordedEvidence- NCT06505551 · SCG Cell Therapy Pte. Ltd. · Phase 2 · live · background · “Fludarabine” · registered Jul 2024
- NCT05357027 · TCRCure Biopharma Ltd. · Phase 2 · background · “Fludarabine” · registered Jan 2022
| Beijing Biotech18% of its industry studies | 22 studies | 11 study | background 2 |
CyclophosphamideRecent, repeatedEvidence- NCT06505551 · SCG Cell Therapy Pte. Ltd. · Phase 2 · live · background · “Cyclophosphamide” · registered Jul 2024
- NCT05357027 · TCRCure Biopharma Ltd. · Phase 2 · background · “Cyclophosphamide Capsules” · registered Jan 2022
| Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed | 22 studies | 11 study | background 2 |